Work Here?
About Unlearn AI
Industries
AI & Machine Learning
Healthcare
Company Size
51-200
Company Stage
Series C
Total Funding
$130.7M
Headquarters
San Francisco, California
Founded
2017
Overview
Unlearn.AI creates digital twins of patients using artificial intelligence, which are virtual replicas that simulate potential health outcomes. This technology helps healthcare providers predict how a patient's health may change over time, allowing for more informed treatment decisions. The primary clients include healthcare providers and pharmaceutical companies, who can use these digital twins in clinical trials to replace traditional control groups, potentially speeding up drug development and approval processes. Unlearn.AI stands out in the digital health market by offering a service or subscription model for access to its simulation technology, which is increasingly in demand due to the digital transformation in healthcare. The company's goal is to enhance decision-making in patient care and drug development through precise health outcome predictions.
Simplify's Take
What believers are saying
- AI in clinical trials market expected to reach $2.74 billion by 2030.
- Partnership with ProJenX highlights AI's potential in specific therapeutic areas.
- TwinRCT 3.0 enhances decision-making in Phase II trials for better outcomes.
What critics are saying
- Over-reliance on AI data may lead to inaccuracies in trial outcomes.
- Increased competition from companies like Consilx and Aicure could impact market share.
- High clinical trial failure rates could affect perception of Unlearn AI's effectiveness.
What makes Unlearn AI unique
- Unlearn AI's TwinRCT uses digital twins to enhance clinical trial precision.
- The company offers TrialPioneer, a free tool for innovative trial design exploration.
- Unlearn AI's digital twin technology reduces the need for human control groups.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$130.7M
Above
Industry Average
Funded Over
5 Rounds
Insight PartnersIndustry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Holidays
Commuter Benefits
Paid Parental Leave
Company Equity
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 1%2 year growth
↑ 1%DELRAY BEACH, Fla., Dec. 17, 2024 /PRNewswire/ -- The global artificial intelligence in clinical trials market is forecasted to grow steadily from US$1.20 billion in 2023 to US$1.35 billion in 2024, ultimately reaching an impressive US$2.74 billion by 2030, driven by a robust CAGR of 12.4%. Some of the key elements fueling the expansion of the AI in clinical trials market, are the high rate of clinical trial failures, the increasing need of anticipating drug pharmacokinetics, pharmacodynamics, and management of toxicity. According to a research article published by the National Library of Medicine in February 2022, the drug discovery and development process takes about 10-15 years for a new drug to be approved for clinical use. And 90% of the drug candidates fail during the phases I, II, and III of clinical trials and drug approvals. The reasons that may result in failure include but not limited to effectiveness in a clinical setting, high levels of toxicity that cannot be managed, suboptimal drug-like characteristics, a lack of real commercial drivers, and poor strategic design
Clinical-stage biotechnology company ProJenX has announced a collaboration with Unlearn to implement generative AI technology for a Phase I PRO-101 trial of prosetin, a potential amyotrophic lateral sclerosis (ALS) treatment.
To deal with the difficulty of conducting these clinical trials, Eisai invested in Unlearn.AI, Inc. ("Unlearn") in 2020.
Artificial intelligence (AI) is transforming industries and revolutionizing the way we live and work. As AI technology continues to advance at a rapid pace, startups are at the forefront of driving innovation and developing groundbreaking solutions. From advanced language models and image generation to automated machine learning and collaborative data science platforms, these startups are pushing the boundaries of what’s possible with AI. Here are 25 groundbreaking startups shaping the future of AI:1. BriefBrief is a news curation and summarization platform that uses AI to provide a more efficient way for people to stay informed on topics they care about. It curates and summarizes news articles into concise, easy-to-digest summaries, covering over 25 diverse topics.2
SAN FRANCISCO--(BUSINESS WIRE)--Unlearn®, a leader in artificial intelligence research in medicine, today announced the appointment of Steve Herne as its first Chief Commercial Officer. Herne will spearhead commercial strategies to propel the company’s growth following their successful Series C funding. "Things continue to move fast at Unlearn, and Steve’s proven track record in healthcare innovation makes him the perfect leader to shape our commercial strategy,” said Charles Fisher, Ph.D., founder and CEO of Unlearn. Herne, with over 25 years of experience in the pharmaceutical research and development market, has previously led long-term strategic direction as Chief Commercial Officer at WCG and Bioclinica. Herne's impressive career also includes leadership positions at ERT, Icon Development Solutions, Covance, MDS Pharma Services, and Inveresk Research
Unlearn AI is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Unlearn AI
About Unlearn AI
Industries
AI & Machine Learning
Healthcare
Company Size
51-200
Company Stage
Series C
Total Funding
$130.7M
Headquarters
San Francisco, California
Founded
2017
Unlearn AI is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Unlearn AI